Cardiac tamponade during pembrolizumab treatment in a patient with ovarian cancer: a case report.

IF 0.5 Q4 ONCOLOGY

International Cancer Conference Journal Pub Date : 2023-07-05 eCollection Date: 2023-10-01 DOI:10.1007/s13691-023-00621-x

Wei-Ting Sung, Kunihiro Sakai, Haruka Etou, Rikiko Yamamichi, Tomoko Yoneda, Toshiaki Matsuura, Tomoyoshi Maruyama, Daisuke Nishi

引用次数: 0

Abstract

We present the case of a 39-year-old woman with platinum-resistant ovarian cancer who was treated with pembrolizumab. After five cycles of pembrolizumab treatment, she suddenly developed cardiac tamponade with a pleural effusion. The malignant pericardial and pleural effusion had increased, while the other malignant lesions had diminished in size. After pericardial and pleural drainage, no re-accumulation occurred. Pembrolizumab was continued and the patient did not have tumor progression for > 20 months. In some patients with pembrolizumab-induced cardiac tamponade, continuation of pembrolizumab treatment may be possible if other lesions decrease in size and the pericardial effusion can be controlled after drainage.

查看原文本刊更多论文

一例卵巢癌症患者pembrolizumab治疗期间心脏压塞：病例报告。

我们报道了一例39岁的癌症患者，她接受了pembrolizumab治疗。经过五个周期的pembrolizumab治疗后，她突然出现心脏压塞并伴有胸腔积液。恶性心包积液和胸腔积液增加，而其他恶性病变的体积缩小。心包和胸膜引流后，没有再积聚。继续使用Pembrolizumab，患者在 > 20个月。在一些由pembrolizumab引起的心脏压塞患者中，如果其他病变的大小减小，并且引流后心包积液可以得到控制，则可能继续进行pembrolizhumab治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Cancer Conference Journal ONCOLOGY-

自引率

14.30%

发文量

期刊介绍： This online-only journal publishes original case reports on all types of cancer. In particular, we welcome not only case reports of educational value in the diagnosis and treatment of cancers, but also reports on molecularly analyzed cancer cases, including gene mutations, gene fusions, gene expression, and changes in copy number, regardless of their known clinical significance. Assessing the molecular analysis of a tumor usually requires a “cancer conference” in which experts from various fields discuss it. Even if the authors and their respective “cancer conference” were unable to determine the clinical significance of molecular changes at the time of submission and publication, their data may provide evidence that will help the scientific community develop precision medicine solutions in the future. We welcome case reports with reviews of the literature on similar cases, as they are more useful and valuable to readers than are reports of rare cases. International Cancer Conference Journal is the official publication of the Japan Society of Clinical Oncology (JSCO). - Presents an online-only collection of original case reports on all types of cancer - In particular, welcomes molecularly analyzed cancer cases - The Official Publication of the Japan Society of Clinical Oncology (JSCO)